JP2011516672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516672A5 JP2011516672A5 JP2011503216A JP2011503216A JP2011516672A5 JP 2011516672 A5 JP2011516672 A5 JP 2011516672A5 JP 2011503216 A JP2011503216 A JP 2011503216A JP 2011503216 A JP2011503216 A JP 2011503216A JP 2011516672 A5 JP2011516672 A5 JP 2011516672A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disease
- pharmaceutical composition
- composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical class CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 2
- 229940013085 2-diethylaminoethanol Drugs 0.000 claims description 2
- 239000004475 Arginine Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical class NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical class OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 239000004472 Lysine Chemical class 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical class CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical class OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical class CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical class OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical class CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 5
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 229940099552 hyaluronan Drugs 0.000 claims 3
- 229920002674 hyaluronan Polymers 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000029936 alkylation Effects 0.000 claims 2
- 238000005804 alkylation reaction Methods 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010057380 Allergic keratitis Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000018035 Dental disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000025157 Oral disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063562 Radiation skin injury Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000014151 Stomatognathic disease Diseases 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 229940124575 antispasmodic agent Drugs 0.000 claims 1
- -1 antispasmodics Substances 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 125000000600 disaccharide group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000030194 mouth disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000006934 radiodermatitis Diseases 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000019635 sulfation Effects 0.000 claims 1
- 238000005670 sulfation reaction Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940127230 sympathomimetic drug Drugs 0.000 claims 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 1
- 239000005750 Copper hydroxide Substances 0.000 description 1
- 101000821981 Homo sapiens Sarcoma antigen 1 Proteins 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 102100021466 Sarcoma antigen 1 Human genes 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001956 copper hydroxide Inorganic materials 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000003196 serial analysis of gene expression Methods 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4231008P | 2008-04-04 | 2008-04-04 | |
| US61/042,310 | 2008-04-04 | ||
| PCT/US2009/039498 WO2009124266A2 (en) | 2008-04-04 | 2009-04-03 | Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516672A JP2011516672A (ja) | 2011-05-26 |
| JP2011516672A5 true JP2011516672A5 (https=) | 2012-05-24 |
| JP5758797B2 JP5758797B2 (ja) | 2015-08-05 |
Family
ID=41055226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011503216A Active JP5758797B2 (ja) | 2008-04-04 | 2009-04-03 | アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7855187B1 (https=) |
| EP (1) | EP2281008B1 (https=) |
| JP (1) | JP5758797B2 (https=) |
| KR (1) | KR101594552B1 (https=) |
| CN (1) | CN102177180A (https=) |
| AU (1) | AU2009231634B2 (https=) |
| BR (1) | BRPI0909849A2 (https=) |
| CA (1) | CA2719666C (https=) |
| MX (1) | MX2010010904A (https=) |
| WO (1) | WO2009124266A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20190691T1 (hr) | 2008-03-27 | 2019-07-12 | Purdue Research Foundation | Sintetički peptidoglikani koji vezuju kolagen, priprema, i postupci upotrebe |
| AU2009231634B2 (en) * | 2008-04-04 | 2014-05-15 | University Of Utah Research Foundation | Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof |
| US8343942B2 (en) * | 2008-04-04 | 2013-01-01 | University Of Utah Research Foundation | Methods for treating interstitial cystitis |
| WO2011094149A1 (en) * | 2010-01-26 | 2011-08-04 | University Of Utah Research Foundation | Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers |
| CA2790682C (en) * | 2010-03-03 | 2020-11-24 | Neocutis Sa | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds |
| US20130209531A1 (en) | 2010-06-08 | 2013-08-15 | University Of Utah Research Foundation | Applications of partially and fully sulfated hyaluronan |
| CA2830933A1 (en) | 2011-03-23 | 2012-09-27 | University Of Utah Research Foundation | Methods for treating or preventing urological inflammation |
| KR20140042795A (ko) * | 2011-03-23 | 2014-04-07 | 유니버시티 오브 유타 리서치 파운데이션 | 비뇨기 염증을 치료 또는 예방하는 방법 |
| EP3208278B1 (en) | 2011-05-24 | 2018-10-31 | Symic IP, LLC | Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use |
| JP5873319B2 (ja) * | 2011-12-16 | 2016-03-01 | 株式会社コーセー | メイラード反応阻害剤 |
| WO2013095215A1 (en) * | 2011-12-19 | 2013-06-27 | Dilaforette Ab | Low anticoagulant heparins |
| RU2617764C2 (ru) | 2011-12-19 | 2017-04-26 | Дилафор Аб | Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение |
| CN104411316B (zh) | 2012-05-09 | 2018-05-01 | 坎泰克斯制药股份有限公司 | 骨髓抑制的治疗 |
| US9688724B2 (en) | 2012-05-14 | 2017-06-27 | University Of Southern California | Methods for limiting development of a skin wound |
| US9717752B2 (en) | 2012-05-15 | 2017-08-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Uses of antagonists of hyaluronan signaling |
| US9828444B2 (en) * | 2012-12-12 | 2017-11-28 | Solvay Specialty Polymers Italy S.P.A. | Fluorinated chitosan derivatives |
| WO2014144969A1 (en) | 2013-03-15 | 2014-09-18 | Purdue Research Foundation | Extracellular matrix-binding synthetic peptidoglycans |
| EP2807925A1 (en) * | 2013-05-26 | 2014-12-03 | Symrise AG | Antimicrobial compositions |
| ES2837626T3 (es) | 2013-07-10 | 2021-07-01 | Matrix Biology Inst | Composiciones de hialuronano con alta elasticidad y usos de las mismas |
| CA2928585A1 (en) * | 2013-10-22 | 2015-04-30 | Cantex Pharmaceuticals, Inc. | Methods of treating and preventing radiation damage |
| CA2931726C (en) | 2013-11-25 | 2022-03-15 | Deuteria Biomaterials, Llc | Deuterium-enriched hyaluronan |
| US9637713B2 (en) | 2014-01-10 | 2017-05-02 | Lost Spirits Distillery, Llc | Method for rapid maturation of distilled spirits using light and heat processes |
| US10947488B2 (en) | 2014-01-10 | 2021-03-16 | Lost Spirits Technology Llc | Method for rapid maturation of distilled spirits using light and heat processes |
| US9637712B2 (en) | 2014-01-10 | 2017-05-02 | Lost Spirits Distillery, Llc | Method for rapid maturation of distilled spirits using light and heat processes |
| US10508259B2 (en) | 2014-01-10 | 2019-12-17 | Lost Spirits Technology Llc | Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes |
| WO2015164822A1 (en) | 2014-04-25 | 2015-10-29 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| ES2871199T3 (es) | 2015-09-24 | 2021-10-28 | Matrix Biology Inst | Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas |
| ITUB20155623A1 (it) * | 2015-11-16 | 2017-05-16 | Fidia Farm Spa | Processo migliorato per la produzione di HA solfatato di elevata purezza |
| US11337994B2 (en) | 2016-09-15 | 2022-05-24 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
| US10849914B2 (en) | 2017-06-12 | 2020-12-01 | University Of Utah Research Foundation | Methods for producing chemoembolic agents for the delivery of anti-cancer agents |
| AU2018298224B2 (en) | 2017-07-07 | 2024-08-15 | Symic Ip, Llc | Synthetic bioconjugates |
| US20200237804A1 (en) * | 2017-10-18 | 2020-07-30 | Glycomira Therapeutics, Inc. | Methods and compositions for treating chronic rhinosinusitis |
| CN108586574B (zh) * | 2018-04-26 | 2019-11-12 | 国家海洋局第三海洋研究所 | 氨基葡萄糖肽类化合物及其制备方法与应用 |
| EP3810125B1 (en) | 2018-06-03 | 2025-07-23 | Glycomira Therapeutics, Inc. | Sulfated polysaccharide for use in preventing oral mucositis after exposure to ionizing radiation |
| CN111228653A (zh) | 2018-11-13 | 2020-06-05 | 格莱科米拉治疗公司 | 用电离辐射加强癌症治疗的方法 |
| KR102793214B1 (ko) | 2019-01-30 | 2025-04-08 | 보오슈 앤드 롬 인코포레이팃드 | 가교화 중합체 망상구조물 및 이의 용도 |
| WO2022157307A1 (en) * | 2021-01-22 | 2022-07-28 | Dsm Ip Assets B.V. | Hyaluronic acid as antimicrobial agent for use on the skin |
| WO2022157314A1 (en) * | 2021-01-22 | 2022-07-28 | Dsm Ip Assets B.V. | Hyaluronic acid for use on the skin |
| CN112972490B (zh) * | 2021-03-04 | 2022-02-18 | 中国人民解放军军事科学院军事医学研究院 | 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2599172A (en) | 1948-11-29 | 1952-06-03 | Searle & Co | Sulfuric acid esters of hyaluronic acid and processes for the production thereof |
| US4240163A (en) * | 1979-01-31 | 1980-12-23 | Galin Miles A | Medicament coated intraocular lens |
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| FR2584728B1 (fr) | 1985-07-12 | 1987-11-20 | Choay Sa | Procede de sulfatation de glycosaminoglycanes et de leurs fragments |
| EP0244178A3 (en) | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
| SE453394B (sv) * | 1986-07-07 | 1988-02-01 | Pharmacia Ab | Forfarande for framstellning av sulfaterade polysackarider genom anvendning av ett reducerande medel for sulfateringsreaktionen |
| EP0285357A3 (en) | 1987-03-31 | 1989-10-25 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Control of retroviruses |
| DK505588D0 (da) | 1988-02-26 | 1988-09-09 | Jesper Hamburger | Middel og anvendelse af samme |
| IT1217458B (it) | 1988-05-02 | 1990-03-22 | Crinos Ind Farmacoriologica S | Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche |
| JP2769584B2 (ja) * | 1990-06-04 | 1998-06-25 | 参天製薬株式会社 | 局所投与用抗アレルギー剤 |
| IT1247175B (it) | 1991-04-19 | 1994-12-12 | Fidia Spa | Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico. |
| ES2149178T3 (es) | 1991-08-16 | 2000-11-01 | Miles A Galin | Implante ocular para la camara anterior refractivo, recubierto con un medicamento. |
| ITPD940054A1 (it) * | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
| DE69621528T2 (de) | 1995-02-07 | 2003-01-16 | Shiseido Co. Ltd., Tokio/Tokyo | Anti-inflamatorische agenzien |
| GB2317182B (en) | 1996-09-11 | 2000-11-01 | Johnson & Johnson Medical | Sulfated polysaccharides and uses thereof in medical treatment |
| JPH10195107A (ja) | 1997-01-10 | 1998-07-28 | Shiseido Co Ltd | オリゴ硫酸化ヒアルロン酸 |
| DK0971961T3 (da) * | 1997-04-04 | 2003-03-24 | Fidia Advanced Biopolymers Srl | N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling |
| US5981509A (en) | 1997-05-20 | 1999-11-09 | Shiseido Company, Ltd. | Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide |
| IT1293484B1 (it) | 1997-06-11 | 1999-03-01 | Fidia Advanced Biopolymers Srl | Materiale biologico comprendente una efficiente coltura di cellule e una matrice tridimensionale biocompatibile e biodegradabile |
| IT1294797B1 (it) | 1997-07-28 | 1999-04-15 | Fidia Advanced Biopolymers Srl | Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante |
| ITPD980037A1 (it) | 1998-02-25 | 1999-08-25 | Fidia Advanced Biopolymers Srl | Acido ialuronico solfatato e i suoi derivati legati covalentemente a polimeri sintetici pe la preparazione di biomateriali e per il rivesti |
| DE19813234A1 (de) | 1998-03-26 | 1999-09-30 | Knoell Hans Forschung Ev | Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren |
| JPH11279042A (ja) | 1998-03-30 | 1999-10-12 | Shiseido Co Ltd | 皮膚外用剤 |
| US6984667B2 (en) | 1998-04-08 | 2006-01-10 | Theta Biomedical Consulting And Development Co. | Synergistic proteoglycan compositions for inflammatory conditions |
| ITPD980149A1 (it) | 1998-06-17 | 1999-12-17 | Fidia Advanced Biopolymers Srl | Protesi tridimensionali comprendenti derivati dell'acido ialuronico per riparare o ricostruire i tessuti danneggiati e processo per la |
| US6492503B1 (en) | 1998-07-31 | 2002-12-10 | Seikagaku Corporation | Glycosaminoglycan and drug compositions containing the same |
| IT1303735B1 (it) | 1998-11-11 | 2001-02-23 | Falorni Italia Farmaceutici S | Acidi ialuronici reticolati e loro usi medici. |
| IT1306644B1 (it) | 1999-04-08 | 2001-10-02 | Fidia Advanced Biopolymers Srl | Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico. |
| US6288043B1 (en) | 1999-06-18 | 2001-09-11 | Orquest, Inc. | Injectable hyaluronate-sulfated polysaccharide conjugates |
| JP2001097997A (ja) | 1999-10-01 | 2001-04-10 | Shiseido Co Ltd | 硫酸化ヒアルロン酸を用いたアフィニティー吸着担体及びその使用 |
| JP4139029B2 (ja) * | 1999-12-10 | 2008-08-27 | 大阪瓦斯株式会社 | 電源装置 |
| JP2001163789A (ja) | 1999-12-13 | 2001-06-19 | Maruho Co Ltd | マトリックスメタロプロテアーゼ阻害用医薬組成物 |
| EP1471870B1 (en) | 2000-01-10 | 2014-08-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Use of lipid conjugates in the treatment of disease |
| US6828308B2 (en) * | 2000-07-28 | 2004-12-07 | Sinclair Pharmaceuticals, Ltd. | Compositions and methods for the treatment or prevention of inflammation |
| IT1317359B1 (it) | 2000-08-31 | 2003-06-16 | Fidia Advanced Biopolymers Srl | Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e |
| DE10053053A1 (de) | 2000-10-19 | 2002-05-16 | Knoell Hans Forschung Ev | Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden |
| ITPD20020064A1 (it) | 2002-03-12 | 2003-09-12 | Fidia Advanced Biopolymers Srl | Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem |
| US7030208B2 (en) * | 2002-04-11 | 2006-04-18 | Carbomer, Inc. | Biocompatible materials and probes |
| WO2003086474A2 (en) | 2002-04-11 | 2003-10-23 | Carbomer, Inc | Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri |
| RU2005102604A (ru) | 2002-07-03 | 2005-09-10 | Перикор Сайенс, Инк. (Us) | Композиция гиалуроновой кислоты и способы применения |
| JP2004262777A (ja) * | 2003-02-27 | 2004-09-24 | Shiseido Co Ltd | アセチル化ヒアルロン酸含有眼用医薬組成物 |
| DE10352137A1 (de) | 2003-11-04 | 2005-06-16 | Beschorner, Katharina, Dr. | Verwendung sulfatierter Hyaluronsäure |
| EP1694712A1 (en) | 2003-12-04 | 2006-08-30 | University of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
| FR2864090B1 (fr) * | 2003-12-19 | 2006-01-27 | Aventis Pharma Sa | Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant |
| US20050203056A1 (en) | 2003-12-19 | 2005-09-15 | Aventis Pharma S.A. | Carboxyl-reduced derivatives of hyaluronic acid, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them |
| ITPD20040245A1 (it) | 2004-10-08 | 2005-01-08 | Fidia Advanced Biopolymers Srl | Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali |
| DE102005004643B4 (de) | 2005-01-28 | 2010-04-08 | Innovent E.V. Technologieentwicklung | Antivirale Kombinationen sowie ihre Verwendung |
| JP2006206849A (ja) | 2005-01-31 | 2006-08-10 | Seikagaku Kogyo Co Ltd | アルキルエステル化されたグリコサミノグリカンの製造方法 |
| US20090105463A1 (en) | 2005-03-29 | 2009-04-23 | Massachusetts Institute Of Technology | Compositions of and Methods of Using Oversulfated Glycosaminoglycans |
| WO2006108022A1 (en) | 2005-04-04 | 2006-10-12 | Neoparin, Inc. | Process for the induction of intramolecular migration of sulfates, phosphates, and other oxyanions |
| ITPD20050206A1 (it) * | 2005-07-07 | 2007-01-08 | Fidia Advanced Biopolymers Srl | Biomateriali in forma di fibra da impiegarsi come dispositivi medici nel trattamento delle ferite e loro processi di produzione |
| US7993678B2 (en) | 2005-09-26 | 2011-08-09 | Novozymes Biopolymer A/S | Hyaluronic acid derivatives |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| US20080306022A1 (en) | 2005-10-12 | 2008-12-11 | Kenji Miyamoto | Agent for Applying to Mucosa and Method for the Production Thereof |
| DE602006019474D1 (de) | 2005-11-22 | 2011-02-17 | Ard Sa | Hren dafür und verwendungen davon |
| US20070166266A1 (en) * | 2006-01-19 | 2007-07-19 | Solazyme, Inc. | Methods and compositions for improving the health and appearance of skin |
| DK1994062T3 (da) | 2006-03-02 | 2009-11-16 | Novozymes Biopharma Dk As | Aryl/alkyl-vinylsulfonhyaluronsyrederivater |
| ITPD20060219A1 (it) | 2006-05-31 | 2007-12-01 | Fidia Farmaceutici | Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi |
| US20080032920A1 (en) | 2006-07-11 | 2008-02-07 | Prestwich Glenn D | Macromolecules modified with electrophilic groups and methods of making and using thereof |
| EP2070518A2 (en) | 2006-07-25 | 2009-06-17 | Osmotica Corp. | Ophthalmic solutions |
| TW200838552A (en) | 2007-01-25 | 2008-10-01 | Novozymes Biopolymer As | Methyl esters of hyaluronic acid |
| JP5088864B2 (ja) | 2007-03-16 | 2012-12-05 | オリンパス株式会社 | 生体組織補填材とその製造方法 |
| EP2025687A1 (en) | 2007-07-23 | 2009-02-18 | Istituto Scientifico di Chimica E Biochimica "G Ronzoni | Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby |
| WO2009033047A2 (en) * | 2007-09-07 | 2009-03-12 | University Of Chicago | Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan |
| EP2057983A1 (en) | 2007-11-07 | 2009-05-13 | Bruschettini S.r.l. | Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations |
| US8093365B2 (en) * | 2008-03-03 | 2012-01-10 | New York University | Biocompatible materials containing stable complexes method of TSG-6 and hyaluronan and method of using same |
| US8343942B2 (en) | 2008-04-04 | 2013-01-01 | University Of Utah Research Foundation | Methods for treating interstitial cystitis |
| AU2009231634B2 (en) | 2008-04-04 | 2014-05-15 | University Of Utah Research Foundation | Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof |
| BRPI1007325A2 (pt) | 2009-02-02 | 2019-09-24 | Otsuka Pharma Co Ltd | "baixo peso molecular de polissulfatados derivados de ácido hialurônico e medicamentos que contenham o mesmo." |
| US20100204325A1 (en) | 2009-02-11 | 2010-08-12 | Allergan, Inc. | Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
| IT1393945B1 (it) | 2009-04-21 | 2012-05-17 | Fidia Farmaceutici | Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche |
| IT1397246B1 (it) | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica |
| IT1397247B1 (it) | 2009-05-14 | 2013-01-04 | Fidia Farmaceutici | Nuovi agenti regolatori dell'attivita' citochinica |
| CA2830933A1 (en) | 2011-03-23 | 2012-09-27 | University Of Utah Research Foundation | Methods for treating or preventing urological inflammation |
-
2009
- 2009-04-03 AU AU2009231634A patent/AU2009231634B2/en active Active
- 2009-04-03 JP JP2011503216A patent/JP5758797B2/ja active Active
- 2009-04-03 EP EP09727633.1A patent/EP2281008B1/en active Active
- 2009-04-03 CN CN2009801208979A patent/CN102177180A/zh active Pending
- 2009-04-03 WO PCT/US2009/039498 patent/WO2009124266A2/en not_active Ceased
- 2009-04-03 KR KR1020107024824A patent/KR101594552B1/ko active Active
- 2009-04-03 BR BRPI0909849A patent/BRPI0909849A2/pt not_active IP Right Cessation
- 2009-04-03 CA CA2719666A patent/CA2719666C/en active Active
- 2009-04-03 MX MX2010010904A patent/MX2010010904A/es active IP Right Grant
-
2010
- 2010-08-27 US US12/870,763 patent/US7855187B1/en active Active
- 2010-08-27 US US12/870,774 patent/US8399430B2/en active Active
-
2011
- 2011-11-23 US US13/304,292 patent/US8329673B2/en active Active
-
2013
- 2013-01-07 US US13/735,124 patent/US8951990B2/en active Active
-
2015
- 2015-02-04 US US14/613,523 patent/US9549945B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516672A5 (https=) | ||
| US9511019B2 (en) | Pharmaceutical compositions for treating IBD | |
| JP6389190B2 (ja) | 固溶体組成物および慢性炎症における使用 | |
| JP4542743B2 (ja) | ピリドン誘導体の溶液状医薬組成物 | |
| JP6462045B2 (ja) | スルフォラファンの単離及び精製 | |
| US7854943B2 (en) | Phospholipid gel compositions for drug delivery and methods of treating conditions using same | |
| CN1481246A (zh) | 炎症性呼吸道疾病的预防/治疗剂 | |
| EP2506711A1 (en) | Hypersulfated disaccharide formulations | |
| JP2012526099A5 (https=) | ||
| JP2012518671A5 (https=) | ||
| US20110245197A1 (en) | Hypersulfated glucopyranosides | |
| CN104470510A (zh) | 一种基于前列腺素的支气管松解药 | |
| WO2024193721A1 (zh) | 一种新的2-(1-羟基戊基)苯甲酸环烷胺盐 | |
| WO2020055916A9 (en) | Dithiolsaccharide mucolytic agents and uses thereof | |
| WO2015016698A1 (es) | Composición farmacéutica con agentes antiinflamatorios y proceso de producción | |
| CN105163732A (zh) | 用于治疗眼科疾病和病症的方法 | |
| EP2505195B1 (en) | Topical pharmaceutical compositions of ketoprofen and methylsulfonylmethane | |
| CN1745061A (zh) | 抗炎剂的十六烷基吡啶鎓盐以及含有该盐的药物组合物 | |
| CS197252B2 (en) | Method of producing novel derivatives of oxyphenyl butazone | |
| CN101255117A (zh) | 带一氧化氮供体的非甾体类抗炎药前体药物及其制备方法 | |
| EP2486915A1 (en) | Topical pharmaceutical compositions comprising flurbiprofen and methylsulfonylmethane | |
| EP2340016A2 (en) | Topical formulation of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate | |
| NZ812405B2 (en) | Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson's disease | |
| WO2012101310A1 (es) | Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido nítrico, nitroderivados obtenidos y su uso en tratamiento de úlceras crónicas | |
| NZ812405A (en) | Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson’s disease |